SIBO Breath Test: What This Test Actually Measures

How the Breath Test Works: From Substrate to Exhaled Gas

The test relies on a simple physiological principle. Humans do not produce hydrogen or methane on their own. These gases originate exclusively from microbial fermentation in the gastrointestinal tract. When bacteria encounter unabsorbed carbohydrates, they metabolize them and release H₂, CH₄, or both as byproducts [1].

After an overnight fast of at least 12 hours, you drink a measured dose of either lactulose (10 g) or glucose (75 g) dissolved in water. A baseline breath sample is collected before ingestion. Then samples are taken every 15 to 20 minutes for 90 to 180 minutes, depending on the protocol your clinic follows. Each sample is analyzed using gas chromatography or an electrochemical sensor device calibrated to detect parts-per-million changes in H₂ and CH₄ [2].

These gases diffuse from the intestinal lumen into capillary blood, travel to the lungs, and are exhaled. The breath test captures this transit. Gas levels plotted over time create a curve that clinicians read for early peaks (suggesting small intestinal fermentation) versus late peaks (suggesting colonic fermentation). The entire process is painless, requires no blood draw, and can be performed at home with validated collection kits or in a clinical lab [3].

Hydrogen vs. Methane: Two Distinct Signals

Hydrogen and methane reflect different microbial populations, and the clinical meaning of each gas differs. A hydrogen-dominant result points toward bacterial overgrowth by organisms such as Escherichia coli, Klebsiella, and Streptococcus species that produce H₂ as their primary fermentation byproduct [4].

Methane tells a different story. It is produced not by bacteria but by archaea, primarily Methanobrevibacter smithii. These organisms consume hydrogen and carbon dioxide to generate CH₄. High methane on a breath test has been associated with constipation-predominant symptoms. A 2012 study by Kunkel et al. (N=412) found that patients with methane levels of 3 ppm or higher on lactulose breath testing had significantly slower intestinal transit times compared to hydrogen-dominant subjects (P<0.001) [5]. The 2017 North American Consensus defined methane-positive status at 10 ppm or above at any point during the test, and the condition is now referred to as intestinal methanogen overgrowth (IMO) rather than SIBO when methane is the dominant gas [1].

A third gas, hydrogen sulfide (H₂S), has gained attention since the development of the trio-smart breath test. Dr. Mark Pimentel of Cedars-Sinai stated: "Hydrogen sulfide-producing organisms represent a third pathway of gas production in the gut that we could not previously measure with standard breath testing" [6]. H₂S-dominant overgrowth has been linked to diarrhea-predominant presentations, though consensus thresholds for H₂S remain under active investigation.

What the Numbers Mean: Interpreting Positive and Negative Results

The 2017 North American Consensus, published by Rezaie et al., established the diagnostic cutoffs used by most gastroenterology practices today [1]. These thresholds replaced older, inconsistent criteria that varied widely between laboratories.

A positive hydrogen result requires a rise of 20 ppm or more above the baseline value within the first 90 minutes of the test. Timing matters. A rise that occurs only after 90 minutes more likely reflects normal colonic fermentation, since lactulose (which is non-absorbable) will reach the cecum in most patients by that point. A positive methane result is defined as 10 ppm or more at any single time point, regardless of baseline, because methane production tends to be more stable and does not follow the same rise-from-baseline pattern [1].

A flat-line result, where both H₂ and CH₄ remain below 3 ppm throughout the entire test, does not necessarily mean the gut is free of overgrowth. It may indicate the presence of hydrogen sulfide-producing organisms that consume H₂ without generating methane [6]. The American College of Gastroenterology (ACG) 2020 clinical guideline on SIBO noted that "a negative breath test does not definitively exclude SIBO, particularly when clinical suspicion is high" [7].

Lactulose vs. Glucose: Which Substrate and Why It Matters

The two substrates test different segments of the small intestine, and each has trade-offs in sensitivity and specificity.

Glucose (75 g dose) is absorbed rapidly in the proximal small intestine. This makes it highly specific for detecting overgrowth in the duodenum and proximal jejunum. A 2008 meta-analysis by Khoshini et al. Reported glucose breath test sensitivity of 20% to 93% and specificity of 30% to 86%, depending on the reference standard used [8]. The main limitation: glucose is fully absorbed before reaching the distal small intestine, so overgrowth confined to the ileum will be missed entirely.

Lactulose (10 g dose) is a synthetic disaccharide that humans cannot digest. It passes through the entire small bowel intact before reaching the colon, where resident bacteria ferment it. This broader transit allows detection of distal small bowel overgrowth. The trade-off is reduced specificity. Because lactulose always reaches the colon and produces a late fermentation peak, distinguishing a true early small intestinal peak from early colonic arrival can be difficult. In patients with rapid intestinal transit (common in diarrhea-predominant IBS), colonic gas production may begin before the 90-minute cutoff, producing a false positive [9].

Dr. Ali Rezaie, co-author of the North American Consensus, has noted: "Neither substrate is perfect. Glucose is better when you suspect proximal overgrowth; lactulose provides broader coverage but at the cost of more equivocal results" [10]. Many specialized centers now use glucose as the first-line substrate and reserve lactulose for cases where proximal testing is negative but clinical suspicion persists.

Preparation Protocol: Why the 24-Hour Prep Diet Exists

Improper preparation is the most common reason for uninterpretable breath test results. The preparatory diet eliminates fermentable substrates from the gut so that baseline gas levels are as low as possible. Without this step, residual colonic fermentation from a previous meal can raise baseline hydrogen and obscure the response to the test substrate.

The standard prep protocol involves eating only easily absorbed, low-residue foods for 24 hours before the test: white rice, plain baked or broiled chicken or fish, eggs, and white bread. No dairy, no high-fiber foods, no beans, no fruit, no sugar alcohols. After the 24-hour diet, a 12-hour overnight water-only fast follows [1].

Certain medications also interfere with results. Antibiotics should be stopped at least four weeks before testing. Proton pump inhibitors may alter bacterial populations and should be discussed with the ordering clinician. Prokinetic agents should be discontinued at least three days prior. On the morning of the test, patients should avoid smoking and vigorous exercise, both of which can alter breath CO₂ and H₂ concentrations [2]. Brushing teeth with a small amount of toothpaste followed by a chlorhexidine mouthwash rinse reduces oral bacterial fermentation, which can cause a false early hydrogen spike in the first 15 minutes of testing.

Accuracy and Limitations: What the Evidence Shows

No breath test achieves perfect accuracy for SIBO diagnosis. The reference standard, jejunal aspirate culture with a colony count exceeding 10³ CFU/mL (revised downward from the older 10⁵ threshold), is itself imperfect because it samples only one location in the small bowel and may miss patchy overgrowth [7].

A 2020 systematic review by Losurdo et al. Examined 14 studies comparing breath testing against jejunal aspirate and found pooled sensitivity of 54.5% for lactulose and 51.8% for glucose, with pooled specificity of 83.3% and 85.7%, respectively [11]. These numbers confirm that breath testing is better at ruling in SIBO (reasonable specificity) than at ruling it out (modest sensitivity).

Several factors can cause false results. False positives arise from rapid orocecal transit, incomplete prep, and oral bacterial contamination. False negatives occur in patients whose overgrowth involves non-hydrogen, non-methane-producing species, or when overgrowth is confined to a segment that the chosen substrate does not reach. Patients taking antibiotics within the washout window will suppress bacterial gas production and test falsely negative.

Despite these constraints, the ACG 2020 guideline conditionally recommends glucose or lactulose breath testing as a diagnostic tool for SIBO, citing its non-invasive nature and acceptable specificity when proper preparation protocols are followed [7].

Clinical Context: When Clinicians Order This Test

Breath testing for SIBO is not a screening test for the general population. It is ordered when a patient presents with specific symptom patterns and risk factors that raise clinical suspicion for small intestinal bacterial overgrowth.

Common indications include chronic bloating and abdominal distension, excessive flatulence, diarrhea or constipation (particularly when alternating), abdominal pain that worsens after meals, and unexplained nutrient malabsorption such as iron deficiency or vitamin B12 deficiency despite adequate dietary intake [7]. Risk factors that increase pretest probability include prior abdominal surgery (especially ileocecal valve resection), motility disorders such as gastroparesis or scleroderma, chronic use of proton pump inhibitors, small bowel diverticula, and conditions affecting the migrating motor complex [12].

The test is also used to monitor treatment response. A follow-up breath test performed two to four weeks after completing antibiotic therapy (typically rifaximin 550 mg three times daily for 14 days) can show whether gas levels have normalized. In the TARGET 3 trial (N=636), rifaximin produced a significantly higher rate of breath test normalization compared to placebo in IBS patients with abnormal baseline lactulose breath tests [13]. Persistent elevation on repeat testing may prompt a second course of treatment or investigation for an underlying anatomical or motility cause.

Emerging Technologies: Beyond Standard H₂ and CH₄

Breath test technology continues to evolve. The addition of hydrogen sulfide measurement through the trio-smart device (developed by Gemelli Biotech) expanded the diagnostic window to capture a third fermentation pathway. Early data suggest that approximately 30% of patients with IBS-D symptoms and a "flat-line" standard breath test may have elevated H₂S, though validated cutoffs have not yet been established in consensus guidelines [6].

Point-of-care and home-based breath testing devices have also changed how the test is administered. Companies now offer FDA-cleared home collection kits with validated bag-based sampling that patients mail to a central laboratory. A 2019 study by Leite et al. At Cedars-Sinai demonstrated that home-collected samples showed comparable accuracy to in-office testing when preparation instructions were followed correctly [14].

Research into volatile organic compounds (VOCs) in exhaled breath represents the next frontier. Machine learning algorithms applied to VOC profiles may eventually distinguish SIBO subtypes, predict treatment response, and differentiate SIBO from other functional gut disorders without relying on a single gas threshold. These approaches remain investigational, with no clinical-grade VOC breath test available for SIBO as of mid-2026.

How Results Connect to Treatment Decisions

Breath test results directly inform treatment selection. Hydrogen-dominant SIBO is treated with rifaximin 550 mg three times daily for 14 days, based on the TARGET trials that showed a 9.8% absolute improvement in adequate relief of IBS symptoms over placebo in TARGET 1 and TARGET 2 (N=1,260 combined) [13].

Methane-dominant results (IMO) typically require combination therapy. The most studied regimen pairs rifaximin with neomycin 500 mg twice daily for 14 days. A study by Pimentel et al. (N=84) found that this combination normalized methane on breath testing in 85% of patients, compared to 33% with rifaximin alone [15]. Some clinicians substitute metronidazole for neomycin due to neomycin's ototoxicity risk with repeated courses.

Hydrogen sulfide-dominant presentations lack a consensus antibiotic protocol. Bismuth subsalicylate has shown sulfide-binding properties in preliminary studies, and some practitioners use it adjunctively. Dietary interventions, particularly limiting sulfur-rich foods (cruciferous vegetables, eggs, red meat), are often trialed alongside antimicrobial therapy.

Repeat breath testing at the 2-to-4-week post-treatment mark guides the decision to stop therapy, extend a course, or investigate structural causes. A normalized breath test with persistent symptoms should prompt evaluation for other diagnoses, including celiac disease, pancreatic exocrine insufficiency, or bile acid malabsorption.